Close Menu

NEW YORK (360Dx) – Ortho Clinical Diagnostics and Beijing Leadman Biochemistry have collaborated to launch four assays for the Chinese market today.

The assays are cystatin C for the early diagnosis of chronic kidney disease; α-hydroxybutyrate dehydrogenase for the diagnosis of a heart attack; homocysteine for assessing risk factors for coronary atherosclerosis, Alzheimer's disease, venous embolism, neonatal defects, and habitual abortion; and total bile acids for the early detection of liver injury.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.